What Your FDA / CE / Reference Approvals Unlock, by Country
A country-by-country matrix of what an existing FDA, CE, or other reference-market approval actually unlocks: which regulators run a named, formally timed reliance or abridged route, which references qualify for it, and what every route — formal or not — never waives.
The core distinction
There are two entirely different things manufacturers call "using my FDA/CE approval," and conflating them is the single most common planning mistake on this topic. A FORMAL reliance or abridged route is a named program with a defined eligible-authority list and a published or targeted timeline — Singapore's Abridged/Immediate/Expedited routes, Saudi Arabia's Abridged Review, Brazil's RDC 741/2022 AREE pathway, Mexico's Vía Regulatoria Abreviada, South Korea's Abbreviated Review (약식심사), Malaysia's Verification Route, and the Philippines' FDC 2022-008 abridged clock all fit this description, and each one names its own specific set of qualifying reference agencies — the lists are not identical, and CE is excluded from several of them (Brazil, Mexico's older Acuerdo de Equivalencia) even where FDA and Health Canada are included. REFERENCE EVIDENCE, by contrast, is what happens in every other country on this page: the FDA or CE dossier is accepted as strong supporting technical or clinical evidence inside the standard review, reducing deficiency-query rounds and documentation-preparation effort, but it does not create a separate, faster procedural track or a published timeline commitment. Vietnam, Japan, China, the UK, the EU, the US, and Canada all fall into this second category for most or all reference certificates — even where the acceleration effect is real and well-documented, as with FDA data in Japan's PMDA review or CE technical files in a US 510(k) submission. No formal route, anywhere, waives the local regulatory-holder requirement, local-language labelling, or the jurisdiction's own classification and post-market obligations.
Country-by-country leverage matrix
| Country | Formal route? | Which references qualify | What is NOT waived |
|---|---|---|---|
| Singapore | FORMAL — HSA Reference Market system: Abridged (Class B/C/D, targets 100/160/220 working days), Immediate/Expedited (Class B same-day to 40 working days, Class C ~ECR-1/ECR-2, Class D EDR) | Exactly 5 named agencies: US FDA (510(k)/De Novo/PMA), EU Notified Body CE (direct NB review, not MRA-based; Class I self-declared CE does not qualify), Australia TGA (direct conformity assessment), Japan PMDA, Health Canada | Singapore-based Registrant and, for import/supply, a licensed Dealer; English labelling and GDPMDS/QMS duties; automatic classification mapping does not occur — HSA applies its own GN-13/GN-14 rules |
| Philippines | FORMAL, but ASEAN-NRA-only — FDA Circular 2022-008 Abridged Processing, ~30 business days, Class B/C/D; CE/US FDA do NOT trigger it on their own | Abridged clock: prior approval from any ASEAN-member NRA only (e.g. Singapore HSA, Malaysia MDA, Thailand FDA). Standard CMDR dossier evidence: Australia, Canada, EU, Japan, US named as recognized reference countries — CE/FDA strengthen the standard file but do not themselves unlock the abridged clock | LTO-holder (licensed Philippine importer/distributor must hold the CMDN/CMDR); notarization + Apostille authentication chain (2–4 months); English/Filipino labelling; grouping rules (Single/Family/System/Set) governing application count |
| Thailand⚑ | FORMAL — Expedited Review (roughly halves standard review, removes Specialist Review risk), plus a separate Singapore HSA Reliance Route bypassing Specialist Review | Expedited Review: ≥1 year of approval from US FDA, an EU Notified Body, Australia TGA, Health Canada, Japan MHLW, or WHO Prequalification. HSA Reliance Route: a submission technically identical to the file already approved by Singapore HSA, plus HSA registrant consent to share documentation | Thai establishment-license holder; Thai-language labelling; CSDT-format submission; the 5-year validity/renewal cycle |
| Malaysia⚑ | FORMAL, two distinct tracks — CE/FDA recognition inside the standard conformity-assessment process (simplified pathway for Class A/B; fewer deficiency queries for C/D), plus the Verification Route (MDA/GD/0070): CAB ~30 working days + MDA ~30 working days ≈ 3 months total, permanent policy since 1 March 2026 | CE/FDA recognition: MDR-issued CE (preferred over legacy MDD) and full-technical-summary FDA 510(k)/De Novo/PMA. Verification Route: Singapore HSA and Thailand TFDA prior approval only — a bidirectional Malaysia–Thailand pilot (Feb–Apr 2026) further compressed both directions | Malaysia-incorporated AR holding an Establishment Licence and GDPMD certificate; English/Bahasa Malaysia labelling; automatic classification mapping does not occur; CAB conformity assessment for Class C/D is reduced in query volume but not removed |
| Vietnam⚑ | NONE — no formal, procedurally separate fast-track exists; reference-country evidence functions as a near-prerequisite for Type B/C/D, not an accelerant to a separate track | EU CE and US FDA both accepted as overseas-registration proof under Decree 98/2021, with equivalent evidentiary weight; FDA PMA clinical data can substitute for local clinical evidence on Type D devices specifically | Vietnamese Authorized Representative; mandatory Vietnamese-language labelling; local Vietnamese technical testing for Type C/D (some products still require it even with a strong CE/FDA file); no separate faster procedural track exists to opt into |
| Indonesia | NONE — no formal expedited or abbreviated registration route for CE/FDA-marked products; evidence reduces technical queries within the standard ASEAN CSDT review only. Exception: for certain high-risk IVD categories, reference-country approval is a mandatory precondition, not an optional accelerator | EU CE (Notified-Body-issued; self-declared does not qualify) and US FDA (PMA most impactful for Class D clinical-query reduction) accepted as core CSDT supporting evidence; high-risk IVD precondition names EU, US, Japan, and others generally | Independent SNI certification where applicable; Halal certification for Class A devices with animal-derived materials from 18 Oct 2026 (phased through 2039); mandatory Bahasa Indonesia labelling; mandatory local licence-holder mode |
| Japan | NONE tied to FDA/CE specifically — Japan’s formal acceleration levers (SAKIGAKE, 6-month target; Conditional Approval System) require Japan-first or Japan-simultaneous filing intent and genuine innovativeness, not simply holding a reference-market approval | FDA 510(k)/PMA data broadly reused as supporting technical evidence in PMDA review and cited as a supporting (not codified) SAKIGAKE factor; CE MDR technical files reusable via the shared IMDRF STED structure for document-preparation efficiency only | MAH/D-MAH requirement; Japanese-language labelling and electronic package insert; QMS Ordinance No. 169 conformity; PMDA can still request supplementary Japanese-population bridging data even with both FDA PMA and EU MDR CE already in hand |
| South Korea | FORMAL, FDA-specific only — Abbreviated Review (약식심사): for defined product categories, bypasses detailed technical-document review, compressing a 12–18 month standard review toward roughly 4–8 months | US FDA 510(k)/PMA only, and only for categories confirmed via MFDS’s 사전검토 (pre-review consultation) system. CE is not eligible for Abbreviated Review — it is reused for IMDRF-STED-structured document drafting and supports (but does not itself satisfy) the overseas-marketing Certificate of Free Sale requirement | Korea License Holder (KLH); Korean-language labelling (14-element requirement, MFDS Notice 2022-110); KGMP evidence; periodic post-market re-evaluation cycle |
| China⚑ | NONE — no FDA/CE-keyed reliance or mutual-recognition mechanism; every application completes the full statutory review regardless of foreign approval | Clinical-evaluation exemption catalogue (免于临床评价医疗器械目录, category-based, not certificate-triggered), predicate/equivalent-device comparison (同品种比对) using overseas marketing and clinical data, and CE/FDA technical files restructured as clinical-evaluation source material; strong overseas marketing history (≥5 years, no serious adverse events) supports evaluation exemption arguments | The full statutory review process; Class III local clinical evidence absent a specific exemption; automatic classification mapping does not occur; volume-based procurement (VBP) exposure; the 18–30 month Class III timeline window |
| India⚑ | FORMAL but discretionary — CDSCO’s Central Licensing Authority (CLA) may exempt or abbreviate the Indian clinical-investigation requirement for a device marketed ≥2 years in a recognized reference jurisdiction, contingent on CLA being independently satisfied with the submitted safety/performance data | Six named reference jurisdictions: Australia, Canada, the European Union, Japan, the United Kingdom, and the United States — each requiring ≥2 years of clean market history in the relied-upon jurisdiction. China’s NMPA is not on this list | Authorised Agent / Form MD-15 requirement; local BIS/NABL testing where independently mandated; BIS mandatory certification; MDR 2017 labelling compliance; the classification and licensing process itself |
| Taiwan⚑ | FORMAL for CE and FDA, via distinct mechanisms — CE: Abbreviated Technical File route cutting review by roughly 40%; FDA: submission built around the 510(k)/PMA Summary in place of an independent TFDA technical file, Class II toward 6–9 months | US FDA 510(k)/PMA (strongest leverage) and Notified-Body-issued EU CE (self-declared Class I does not qualify) both have named formal mechanisms; Japan PMDA approval is accepted as supporting evidence only, with no separately named fast-track confirmed | Taiwanese local agent; Traditional Chinese labelling; QSD/GMP evidence; automatic classification mapping does not occur; China’s NMPA is not recognized on political grounds and can draw added scrutiny rather than credit |
| Australia | FORMAL — Overseas Conformity Assessment (OCA) Evidence system: for Class IIb/III/AIMD, a qualifying CE or FDA approval substitutes for TGA’s own independent technical assessment, leaving only administrative conformity checking | EU CE issued by a NANDO-listed Notified Body, and US FDA 510(k)/De Novo/PMA — both recognized at the identical, highest OCA tier | Australian Sponsor (the ARTG registration holder, must be an Australian legal entity); Australian labelling including Sponsor information and the ARTG number; the OCA evidence scope must fully match the ARTG application scope; NMPA is not a recognized OCA evidence type at all |
| Saudi Arabia | FORMAL — SFDA Abridged Review: Class C toward 6–12 months (vs. 12–24 months Full), Class D toward 9–18 months (vs. 18–36+ months Full) | Five named reference agencies at formally equal standing: US FDA, EU Notified Body CE, Australia TGA, Japan PMDA, and Health Canada | Saudi Authorized Representative filing through PRISM; Arabic labelling and (for professional-use devices) Arabic IFU; automatic classification mapping does not occur; Saudi-specific technical queries can still arise even under Abridged Review |
| Brazil | FORMAL — Regulatory Reliance ("via AREE") under RDC 741/2022 + IN 290/2024, Class III/IV Registro petitions only, cited as roughly a 30% reduction in ANVISA’s own analysis time. Separately, MDSAP audit-report reliance can waive ANVISA’s own on-site inspection for BGMP certification and extends BGMP validity to 4 years | Exactly 4 named AREEs: US FDA, Health Canada, Australia TGA, and Japan MHLW/PMDA. The EU (CE, MDR or legacy MDD) is explicitly NOT on this list, and neither is China’s NMPA | BRH (Brazil registration holder) with an AFE; Portuguese-language labelling/IFU; BGMP certification itself for Class III/IV; INMETRO (electro-medical) and ANATEL (RF-connected) certification; apostille + certified-translation authentication chain for the foreign approval document |
| Argentina | FORMAL but risk-class-limited — Decreto 892/25 sworn-declaration reliance: Clase I/II devices and IVD Clase A/B (non-cold-chain) are exempt from local testing and cleared via sworn-declaration notification instead of substantive ANMAT technical review | Seven named jurisdictions in Decreto 892/25 Annex I: Australia, EFTA member states, EU member states, the United States, Israel, Japan, and the United Kingdom, each via a Certificado de Libre Venta. China is not on this list. Clase III/IV devices are excluded entirely — CE/FDA there function only as strong evidentiary support in the standard review, not an exemption | Importador Autorizado / Director Técnico requirement; Spanish-language labelling with certified (Traductor Público) translation; Tecnovigilancia, recall, and post-market inspection obligations; the full Clase III/IV review requirement regardless of reference-country approval |
| Mexico⚑ | FORMAL, two non-identical mechanisms — (1) Acuerdo de Equivalencia (2010/2012): no formal timeline commitment, full Mexican dossier still required; (2) Vía Regulatoria Abreviada (effective Sept 1, 2025): a 30-business-day formal target, but only for "ordinary" (non-accelerated, non-conditional) approvals meeting an "identical essential characteristics" test | Acuerdo de Equivalencia: exactly 3 authorities — US FDA, Health Canada, and Japan MHLW/PMDA (EU CE is not on this list). Vía Regulatoria Abreviada: IMDRF Management Committee member authorities for technical review plus MDSAP-certified sites for GMP evidence — a broader set on paper, but whether CE is enumerated within it is unconfirmed | Mexican legal representative / Licencia Sanitaria requirement; Spanish-language labelling under NOM-137-SSA1-2025; GMP conformity under NOM-241-SSA1-2025; automatic classification mapping does not occur; tecnovigilancia, recall, and post-market inspection obligations |
| Colombia⚑ | NONE confirmed — CE/FDA technical documentation is accepted as clinical/technical evidence inside the standard Clase IIb/III review (180-business-day formal target; 12–36+ month practical range), not a separate legal fast-track. A previously claimed "Registro Sanitario Simplificado" pathway could not be confirmed against an official INVIMA source | CE Mark technical documentation and FDA PMA/510(k) data, accepted in place of or alongside locally generated clinical evidence for Clase IIb/III devices — reduces Requerimiento (deficiency-query) rounds but not the statutory clock | The Registro Sanitario process itself and its formal timeline target; INVIMA’s own classification and review; China’s NMPA carries no recognized weight in either the standard review or informal practice |
| United Kingdom | FORMAL for CE only, and structurally different from a reliance route — CE marking (EU MDR/MDD/IVDR, EU-NB-issued) remains directly valid for GB market access during a transition period extended to 30 June 2030; no separate formal mechanism exists for FDA | EU CE: direct GB market-access equivalence during the transition period, plus direct reuse for an eventual UKCA technical file. US FDA: no formal mechanism — technical documentation reuse only, no timeline compression. China's NMPA: not recognized | UK Responsible Person (UKRP) appointment; MHRA product registration; eventual UKCA marking once the transition ends; the Northern Ireland Windsor Framework runs a parallel EU MDR/UKNI track that is not interchangeable with the GB rule set |
| European Union | NONE for FDA or NMPA — CE marking is the market-access objective itself, not an external accelerator. Legacy MDD/AIMDD CE holders get a defined MDR transitional period (Class III/IIb by Dec 2027, lower-risk by Dec 2028), which is a migration allowance, not a foreign-approval reliance route | US FDA: no formal acceleration mechanism — 510(k)/PMA data is reused as CER literature-review input and risk-management/PMCF evidence, cited as roughly 20–40% documentation-preparation time saved. China’s NMPA: no formal mechanism, cautious literature use only, with ethnic-applicability analysis required | Full Notified Body technical review; ISO 13485 QMS conformity; EU-specific GSPR (MDR Annex I) requirements; the MEDDEV/MDR-specific Clinical Evaluation Report methodology, which differs from the FDA substantial-equivalence framework |
| United States | NONE — FDA does not treat any foreign approval, including CE, as a reference market, and has no official channel for "simplified approval based on CE" | EU CE technical documentation reused for 510(k) substantial-equivalence argumentation or PMA clinical evidence packages — data/document reuse only, explicitly not to be cited to FDA as acceptability evidence in itself. China’s NMPA: neutral, no positive or negative weight | Independent 510(k)/De Novo/PMA review; US-specific standards conformance (ISO/ANSI/ASTM test reports, not Chinese GB/YY standards alone); clinical-evaluation reframing to FDA’s substantial-equivalence or benefit-risk framework |
| Canada | NONE formally named, but both FDA and CE function as strong informal reliance signals — documented cases of some Class II products with FDA 510(k) seeing review streamlined from 6–8 months to roughly 3–4 months, without a separately published program name | US FDA: strongest — Health Canada’s closest international regulatory partner via joint MDSAP participation. EU CE: accepted as supporting technical evidence, cited as reducing MDL documentation workload by roughly 40–60%. China’s NMPA: not recognized | The full Medical Device Licence (MDL) application process; bilingual English/French labelling; the MDSAP requirement for Class II–IV (CE or FDA approval does not itself substitute for MDSAP); classification-mapping differences (a Class II FDA device may be Class III in Canada) |
Reference value chains
Singapore HSA is the region’s most reusable downstream credential
A Singapore HSA registration — itself obtained via Abridged/Immediate/Expedited using FDA/CE/TGA/PMDA/Health Canada evidence — is the ONLY approval type that unlocks the Philippines’ formal ~30-business-day FDC 2022-008 abridged clock (CE/FDA alone do not), and it is a named reference authority inside Malaysia’s Verification Route (MDA/GD/0070, ~3 months total). Vietnamese and Thai reviewers also weigh an existing HSA approval as supporting evidence that reduces deficiency-notice rounds. The practical sequence for Southeast Asia is Singapore first, then use that HSA registration — alongside the original FDA/CE file — to accelerate the Philippines and Malaysia specifically.
MDSAP is a QMS-site credential, and it compounds across four+ markets independently of the device dossier
MDSAP audit reports are a structurally different lever from FDA/CE device-level reliance: Brazil’s ANVISA (an MDSAP founding authority) can waive its own on-site BGMP inspection on the strength of an MDSAP report and extends BGMP validity from 2 to 4 years; Japan’s PMDA (also a founding authority) has directly accepted MDSAP audit reports as QMS Ordinance No. 169 conformity evidence since 2016; Canada makes MDSAP mandatory for Class II–IV, where neither CE nor FDA approval substitutes for it; and Mexico’s 2025 Vía Regulatoria Abreviada names MDSAP-certified sites as the GMP-evidence basis specifically. A single MDSAP audit therefore pays for itself across markets that otherwise have entirely separate device-level reliance rules — including Brazil and Mexico, where CE is structurally excluded from the device-dossier reliance list but MDSAP still helps at the site level.
Saudi Arabia’s SFDA approval carries downstream weight across the rest of the GCC
A Saudi MDMA obtained via Abridged Review is treated as a supporting reference by neighbouring GCC regulators — UAE (MOHAP/DHA/DOH), Qatar (MOH), Kuwait (MOH), Bahrain (NHRA), and Oman (DGSM) — which can reduce deficiency-notice rounds during their own national reviews, even before the planned unified GCCMDR framework is finalized. The recommended sequence for a device already holding FDA or CE is Saudi Arabia first — the region’s most technically rigorous and most strategically referenced approval — then the rest of the GCC.
The narrowest formal reliance lists consistently name FDA, Health Canada, TGA, and PMDA — and just as consistently exclude CE
Brazil’s RDC 741/2022 AREE list (FDA, Health Canada, TGA, MHLW/PMDA) and Mexico’s original Acuerdo de Equivalencia (FDA, Health Canada, MHLW/PMDA) are both built on the identical three-or-four-authority core, and both explicitly exclude the EU/CE from their formal reliance mechanism — even though CE remains strong evidence inside each country’s standard review. A manufacturer whose only reference approval is CE should not assume Brazil or Mexico’s formal reliance routes apply; Singapore and Saudi Arabia, by contrast, both place CE on equal formal footing with FDA.
Go deeper by region or country
This matrix is the cross-country summary. For the full mechanism, timeline, and dossier detail behind any single row, open the country report or the relevant regional entry topic.